

ENDO PHARMACEUTICALS HOLDINGS INC

Form 8-K

June 16, 2003

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 16, 2003 (June 16, 2003)

ENDO PHARMACEUTICALS HOLDINGS INC

---

(Exact name of registrant as specified in its charter)

DELAWARE

39040

13-4022871

---

(State or other  
jurisdiction of  
incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification No.)

100 Painters Drive  
Chadds Ford, Pennsylvania

19317

---

(Address of principal executive offices)

(Zip Code)

(610) 558-9800

---

(Registrant's telephone number, including area code)

N/A

---

(Former name or former address, if changed since last report)

---

**TABLE OF CONTENTS**

Item 7. Financial Statements and Exhibits.

Item 9. Regulation FD Disclosure.

SIGNATURES

---

**Table of Contents**

**Item 7. Financial Statements and Exhibits.**

- (a) *Financial Statements of Business Acquired.*  
Not applicable.
- (b) *Pro Forma Financial Information.*  
Not applicable.
- (c) *Exhibits.*  
Not applicable.

**Item 9. Regulation FD Disclosure.**

The Registrant currently expects net sales in 2003 to be approximately \$520 million, including net sales of Lidoderm® of approximately \$175 million. The Registrant's projections assume that a third party will make available a generic formulation of the Registrant's Percocet® 7.5/325 and Percocet® 10.0/325 late in the third quarter of 2003. The Registrant's projections also assume that it will experience competition with its generic morphine sulfate extended-release product early in the third quarter of 2003.

The Registrant expects net income to be approximately \$92 million or \$.70 per diluted share, which includes charges, net of tax, of approximately \$30 million or \$.23 per diluted share, as recorded in the first quarter of 2003, for non-cash compensation, approximately \$7 million or \$.05 per diluted share for currently anticipated payments to partners for successful achievement of regulatory milestones and approximately \$4 million or \$.03 per diluted share for currently anticipated manufacturing transfer costs.

These amounts do not include the non-cash compensation charge that may arise as a result of the vesting of the approximately 5.0 million outstanding Class C4 stock options. If this vesting occurs, this charge will be substantial. For example, the vesting of the approximately 5.0 million outstanding Class C4 stock options will result in an additional pre-tax compensation charge to the Registrant, which would be approximately \$75 million, if the market price of our stock is \$17.29 on the date vesting occurs.

---

